DK1185294T3 - Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser - Google Patents

Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser

Info

Publication number
DK1185294T3
DK1185294T3 DK00947924T DK00947924T DK1185294T3 DK 1185294 T3 DK1185294 T3 DK 1185294T3 DK 00947924 T DK00947924 T DK 00947924T DK 00947924 T DK00947924 T DK 00947924T DK 1185294 T3 DK1185294 T3 DK 1185294T3
Authority
DK
Denmark
Prior art keywords
disorders
treatment
interpersonal
environment
attenuated
Prior art date
Application number
DK00947924T
Other languages
English (en)
Inventor
Tony Marcel
Francois Rougeon
Catherine Rougeot
Original Assignee
Centre Nat Rech Scient
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Pasteur Institut filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK1185294T3 publication Critical patent/DK1185294T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
DK00947924T 1999-06-23 2000-06-22 Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser DK1185294T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14056399P 1999-06-23 1999-06-23
PCT/EP2000/006259 WO2001000221A2 (en) 1999-06-23 2000-06-22 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
EP00947924A EP1185294B1 (en) 1999-06-23 2000-06-22 Peptides for the treatment of impaired interpersonal and behavioral disorders

Publications (1)

Publication Number Publication Date
DK1185294T3 true DK1185294T3 (da) 2005-08-01

Family

ID=22491816

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05006494T DK1593387T3 (da) 1999-06-23 2000-06-22 Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser
DK00947924T DK1185294T3 (da) 1999-06-23 2000-06-22 Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05006494T DK1593387T3 (da) 1999-06-23 2000-06-22 Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser

Country Status (14)

Country Link
US (2) US7387778B2 (da)
EP (2) EP1593387B1 (da)
JP (1) JP2003512302A (da)
CN (1) CN1189211C (da)
AT (2) ATE414529T1 (da)
AU (1) AU6154700A (da)
CA (1) CA2376935A1 (da)
CY (1) CY1108745T1 (da)
DE (2) DE60040878D1 (da)
DK (2) DK1593387T3 (da)
ES (2) ES2238299T3 (da)
NZ (1) NZ516477A (da)
PT (2) PT1185294E (da)
WO (1) WO2001000221A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
CA2376935A1 (en) 1999-06-23 2001-01-04 Institut Pasteur Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
PT1216707E (pt) * 2000-12-22 2005-06-30 Pasteur Institut Novas utilizacoes terapeuticas para um smr-1-peptideo
EP1911763B1 (en) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
HUE016435T4 (en) 2004-03-19 2017-01-30 Pasteur Institut Peptides derived from human BPLP protein, polynucleotides encoding peptides, and antibodies to peptides
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8889827B2 (en) 2008-04-07 2014-11-18 Institut Pasteur Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases
FR2931362B1 (fr) 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2645452A1 (en) * 2008-11-28 2010-05-28 Institut Pasteur Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
DE102009039655B3 (de) 2009-09-02 2011-03-31 ITT Mfg. Enterprises, Inc., Wilmington UV-Desinfektionseinrichtung für Abwasser und Trinkwasser mit einer Reinigungsvorrichtung
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (da) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc Fremgangsmåde til fremstilling af guanylat-cyclase-c-agonister
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
GB201607814D0 (en) 2016-05-04 2016-06-15 5D Health Prot Group Ltd Anti-microbial compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327966D0 (en) * 1983-10-19 1983-11-23 Nyegaard & Co As Chemical compounds
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US5589189A (en) * 1994-09-14 1996-12-31 Nexstar Pharmaceuticals, Inc. Liposome dispersion
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
CA2376935A1 (en) 1999-06-23 2001-01-04 Institut Pasteur Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
PT1216707E (pt) 2000-12-22 2005-06-30 Pasteur Institut Novas utilizacoes terapeuticas para um smr-1-peptideo

Also Published As

Publication number Publication date
EP1593387B1 (en) 2008-11-19
US20030078200A1 (en) 2003-04-24
CN1356906A (zh) 2002-07-03
JP2003512302A (ja) 2003-04-02
DE60019106T2 (de) 2006-02-16
PT1593387E (pt) 2009-03-18
PT1185294E (pt) 2005-08-31
US7387778B2 (en) 2008-06-17
AU6154700A (en) 2001-01-31
ES2315753T3 (es) 2009-04-01
ATE291927T1 (de) 2005-04-15
EP1593387A1 (en) 2005-11-09
WO2001000221A2 (en) 2001-01-04
US20030186870A1 (en) 2003-10-02
DE60019106D1 (de) 2005-05-04
CY1108745T1 (el) 2014-04-09
CA2376935A1 (en) 2001-01-04
ATE414529T1 (de) 2008-12-15
EP1185294B1 (en) 2005-03-30
NZ516477A (en) 2004-02-27
CN1189211C (zh) 2005-02-16
ES2238299T3 (es) 2005-09-01
WO2001000221A3 (en) 2001-05-03
EP1185294A2 (en) 2002-03-13
DE60040878D1 (de) 2009-01-02
DK1593387T3 (da) 2009-03-02

Similar Documents

Publication Publication Date Title
CY1108745T1 (el) Πεπτιδια δια τη θεραπευτικη αγωγη κακης συμπεριφορας μεταξυ προσωπων
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
MY169308A (en) Treatment of tnf? related disorders
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE325612T1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE430193T1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
IL163026A (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
ATE234089T1 (de) Zubereitungen enthaltend sclareol und sclareolide zur behandlung mikrobieller infektionen
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
TR200200278T2 (tr) Kalsilitik bileşimler
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
ATE399544T1 (de) Synergistische zusammensetzung enthaltend roflumilast und (r,r)-formoterol
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose